Vital Pharma Nordic

Vital Pharma Nordic is a Danish specialty pharmaceutical company that focuses on the licensing, development, and distribution of niche and specialty drugs across the Nordic region. The company's portfolio includes commercialized products such as Dexavit (dexamethasone) and Deflazacort, which are used to treat systemic inflammation and other corticosteroid-responsive conditions. In July 2025, Vital Pharma Nordic was acquired by Unimedic Pharma AB, a Swedish specialty pharma group, to strengthen its presence in the Danish market. The company operates through several subsidiaries, including Frederiksstaden Pharma and XGX Pharma, providing comprehensive market access, packaging, and commercialization services for international partners like Geistlich Pharma.